Stock listing
Tradegate:BXT BioNxt Solutions Inc Aktie
German listing (Tradegate) of BioNxt Solutions Inc · home listing CSE:BNXT
Follow BioNxt Solutions Inc into a list and get an email when it puts out news.
Home listing price · CSE:BNXT
$0.29 CAD +0.01 (+1.8%)
Close on Oct 23, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:BNXT
- Day range
- $0.29 – $0.29 CADOct 23, 2026
- Volume
- 5,500 sharesOct 23, 2026
- Market cap
- $39.47M CADAt the close on Oct 23, 2026 · price × 136.1M shares outstanding
- 52-week range
- $0.265 – $0.87 CADLowest and highest trades, Oct 24, 2025 – Oct 23, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| CSE:BNXT · Home | $0.29 CAD | +0.005 (+1.8%) | 5,500 | $0.29 | $0.29 | $0.29 | $0.285 | Close on Oct 23, 2026 |
| Xetra:BXT | €0.195 EUR | +0.003 (+1.3%) | 850 | €0.196 | €0.196 | €0.195 | €0.192 | Close on Oct 23, 2026 |
| OTC:BNXTF | $0.205 USD | -0.017 (-7.8%) | 5,000 | $0.205 | $0.205 | $0.205 | $0.222 | Close on Oct 19, 2026 |
| Frankfurt:BXT | €0.162 EUR | -0.009 (-5.3%) | — | €0.162 | €0.162 | €0.162 | €0.171 | Close on Oct 23, 2026 |
Daily closes
Last 3 months, Jul 23, 2026 – Oct 23, 2026 · CSE:BNXT · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.29 | +0.005 | +1.8% | $0.29 | $0.29 | $0.29 | 5,500 | |
| $0.285 | +0.02 | +7.5% | $0.29 | $0.29 | $0.285 | 13,500 | |
| $0.265 | -0.035 | -11.7% | $0.33 | $0.33 | $0.265 | 3,000 | |
| $0.30 | +0.015 | +5.3% | $0.30 | $0.30 | $0.30 | 12,000 | |
| $0.285 | -0.015 | -5.0% | $0.29 | $0.29 | $0.27 | 112,636 | |
| $0.30 | 0.00 | 0.0% | $0.31 | $0.31 | $0.30 | 6,000 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 0 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.305 | $0.30 | 54,500 | |
| $0.30 | -0.025 | -7.7% | $0.305 | $0.325 | $0.30 | 44,500 | |
| $0.325 | -0.005 | -1.5% | $0.325 | $0.325 | $0.325 | 6,000 | |
| $0.33 | 0.00 | 0.0% | $0.33 | $0.33 | $0.33 | 0 | |
| $0.33 | 0.00 | 0.0% | $0.35 | $0.35 | $0.325 | 34,500 | |
| $0.33 | -0.01 | -2.9% | $0.33 | $0.33 | $0.33 | 115,000 | |
| $0.34 | -0.04 | -10.5% | $0.35 | $0.35 | $0.34 | 40,541 | |
| $0.38 | +0.04 | +11.8% | $0.36 | $0.38 | $0.36 | 38,000 | |
| $0.34 | -0.01 | -2.9% | $0.335 | $0.34 | $0.33 | 12,500 | |
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 5,000 | |
| $0.35 | +0.015 | +4.5% | $0.36 | $0.36 | $0.35 | 43,000 | |
| $0.335 | -0.005 | -1.5% | $0.34 | $0.34 | $0.335 | 10,000 | |
| $0.34 | 0.00 | 0.0% | $0.34 | $0.345 | $0.34 | 46,100 | |
| $0.34 | -0.07 | -17.1% | $0.34 | $0.34 | $0.34 | 7,300 | |
| $0.41 | 0.00 | 0.0% | $0.41 | $0.41 | $0.41 | 0 | |
| $0.41 | 0.00 | 0.0% | $0.41 | $0.41 | $0.41 | 0 | |
| $0.41 | +0.005 | +1.2% | $0.38 | $0.41 | $0.38 | 50,500 | |
| $0.405 | 0.00 | 0.0% | $0.405 | $0.405 | $0.405 | 0 | |
| $0.405 | +0.015 | +3.8% | $0.405 | $0.405 | $0.405 | 44,444 | |
| $0.39 | +0.05 | +14.7% | $0.35 | $0.39 | $0.34 | 72,000 | |
| $0.34 | 0.00 | 0.0% | $0.34 | $0.34 | $0.34 | 0 | |
| $0.34 | 0.00 | 0.0% | $0.34 | $0.34 | $0.34 | 500 | |
| $0.34 | +0.01 | +3.0% | $0.35 | $0.35 | $0.34 | 20,230 | |
| $0.33 | -0.005 | -1.5% | $0.33 | $0.33 | $0.33 | 98,921 | |
| $0.335 | -0.025 | -6.9% | $0.355 | $0.355 | $0.335 | 36,500 | |
| $0.36 | +0.01 | +2.9% | $0.36 | $0.36 | $0.35 | 126,714 | |
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 | |
| $0.35 | +0.005 | +1.4% | $0.35 | $0.35 | $0.35 | 25,000 | |
| $0.345 | +0.03 | +9.5% | $0.345 | $0.35 | $0.345 | 74,944 | |
| $0.315 | -0.03 | -8.7% | $0.325 | $0.325 | $0.315 | 10,000 | |
| $0.345 | +0.015 | +4.5% | $0.36 | $0.36 | $0.345 | 132,000 | |
| $0.33 | -0.03 | -8.3% | $0.36 | $0.38 | $0.33 | 74,276 | |
| $0.36 | +0.02 | +5.9% | $0.36 | $0.36 | $0.36 | 18,500 | |
| $0.34 | +0.01 | +3.0% | $0.33 | $0.355 | $0.33 | 53,634 | |
| $0.33 | -0.005 | -1.5% | $0.335 | $0.335 | $0.33 | 54,250 | |
| $0.335 | -0.005 | -1.5% | $0.345 | $0.345 | $0.30 | 9,250 | |
| $0.34 | -0.005 | -1.4% | $0.385 | $0.385 | $0.34 | 100,500 | |
| $0.345 | 0.00 | 0.0% | $0.345 | $0.345 | $0.345 | 0 | |
| $0.345 | +0.01 | +3.0% | $0.325 | $0.345 | $0.325 | 20,500 | |
| $0.335 | 0.00 | 0.0% | $0.335 | $0.335 | $0.335 | 500 | |
| $0.335 | 0.00 | 0.0% | $0.335 | $0.335 | $0.335 | 0 | |
| $0.335 | -0.01 | -2.9% | $0.335 | $0.335 | $0.335 | 10,150 | |
| $0.345 | +0.045 | +15.0% | $0.34 | $0.345 | $0.34 | 1,500 | |
| $0.30 | -0.025 | -7.7% | $0.31 | $0.31 | $0.30 | 58,500 | |
| $0.325 | 0.00 | 0.0% | $0.325 | $0.325 | $0.325 | 0 | |
| $0.325 | +0.025 | +8.3% | $0.325 | $0.325 | $0.325 | 4,500 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 0 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 0 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 1,200 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 1,500 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 0 | |
| $0.30 | 0.00 | 0.0% | $0.30 | $0.30 | $0.30 | 0 | |
| $0.30 | -0.005 | -1.6% | $0.30 | $0.30 | $0.30 | 59,196 | |
| $0.305 | -0.005 | -1.6% | $0.305 | $0.305 | $0.305 | 500 | |
| $0.31 | 0.00 | 0.0% | $0.31 | $0.31 | $0.31 | 0 | |
| $0.31 | 0.00 | 0.0% | $0.31 | $0.31 | $0.31 | 0 | |
| $0.31 | +0.01 | +3.3% | $0.335 | $0.34 | $0.305 | 17,347 |
- Ticker
- Tradegate:BXT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Oct 19, 2026
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 27 slides
Latest news
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
Oct 19, 2026
Closed $0.285 (-5.0%) on Oct 19, 2026
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study
Sep 8, 2026
Closed $0.36 (+2.9%) on Sep 8, 2026
BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Aug 21, 2026
Closed $0.335 (-1.5%) on Aug 24, 2026
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
Aug 4, 2026
Closed $0.30 (0.0%) on Aug 4, 2026
BioNxt Solutions Announces Option Grants
Jul 31, 2026
Closed $0.30 (0.0%) on Aug 4, 2026
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
Jul 6, 2026
Closed $0.30 (-9.1%) on Jul 6, 2026
BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 23, 2026
Closed $0.34 (-5.6%) on Jun 24, 2026
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Jun 15, 2026
Closed $0.34 (-4.2%) on Jun 15, 2026
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption
Jun 12, 2026
Closed $0.34 (-4.2%) on Jun 15, 2026
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants
Jun 10, 2026
Closed $0.39 (0.0%) on Jun 11, 2026
Decks
Investor Presentation (September 2026)
Investor deck · 27 slides · September 2026
BioNxt Solutions Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 66 in all · newest Oct 19, 2026 · oldest 2024
- Decks
- 1 deck · latest September 2026
Where BioNxt Solutions Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| CSE:BNXT · Home listing | CSE | Canada | CAD |
| Xetra:BXT | Xetra | Germany | EUR |
| gettex:BXT | gettex | Germany | EUR |
| LS Exchange:A3D1K3 | LS Exchange | Germany | EUR |
| Tradegate:BXT · This page | Tradegate | Germany | EUR |
| Lang & Schwarz:A3D1K3 | Lang & Schwarz | Germany | EUR |
| Cboe Canada:BNXT | Cboe Canada | Canada | CAD |
| OTC:BNXTF | OTC | United States | USD |
| Frankfurt:BXT | Frankfurt | Germany | EUR |
| Dusseldorf:BXT | Dusseldorf | Germany | EUR |
| Hamburg:BXT | Hamburg | Germany | EUR |
| Munich:BXT | Munich | Germany | EUR |
| Stuttgart:BXT | Stuttgart | Germany | EUR |
| Hanover:BXT | Hanover | Germany | EUR |
Log in to ask 6ix AI your own questions about BioNxt Solutions Inc.